SCHEMBL26445194

SCHEMBL26445194

CC(C)CCCCCCCC(=O)NCC(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.51
EPHX2 P34913 4/20 0.47
KDM4C Q9H3R0 2/20 0.46
KDM4A O75164 1/20 0.46
PHF8 Q9UPP1 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C19 P33261 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
BLM P54132 1/20 0.46
PMP22 Q01453 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
DEGS1 O15121 1/20 0.44
FAAH O00519 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21786996 1.00 HPGD (0.51) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL23613251 1.00 HPGD (0.51) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL26445193 1.00 HPGD (0.51) HPGDEPHX2KDM4CKDM4APHF8
Hydrochloric Acid SCHEMBL7280267 0.98 HPGD (0.50) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL21786998 0.98 HPGD (0.53) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL16625022 0.92 HPGD (0.54) HPGDEPHX2CYP2D6CYP2C19CYP1A2
SCHEMBL874764 0.89 ALDH1A1 (0.46) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL24297139 0.86 HPGD (0.44) HPGDEPHX2KDM4CKDM4APHF8
SCHEMBL425951 0.86 ALDH1A1 (0.55) HPGDKDM4CKDM4APHF8KDM2A
SCHEMBL2540536 0.86 KDM4C (0.47) HPGDKDM4CKDM4APHF8KDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024148060-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-07-11 WO disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 HPGD 938/4885EPHX2 635/4885KDM4C 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.